Haleon plc is expected to report Q2 2026 revenue of $3.81 billion and EPS of $0.14, with the current stock price of $11.15 trading below the average analyst price target of $13.50.
Investors are primarily focused on Organic Revenue Growth (ORG) within the company's "Power Brands" portfolio, particularly Sensodyne and Voltaren. Market sentiment remains cautiously optimistic as the company continues to deleverage its balance sheet following the complete exit of legacy shareholders GSK and Pfizer. Analysts are specifically looking for continued operating margin expansion driven by supply chain efficiencies and premiumization strategies across the Oral Health category.